These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 17786611

  • 21. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
    Kitsukawa K.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
    [Abstract] [Full Text] [Related]

  • 22. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML.
    Clin Cancer Res; 2007 Mar 15; 13(6):1883-91. PubMed ID: 17363545
    [Abstract] [Full Text] [Related]

  • 23. Induction of lymphokine-activated cytotoxic T lymphocytes stimulated by dendritic cells and autologous tumor from a patient with gastric cancer and their effects in vitro.
    Yoshikawa T, Yanoma S, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y.
    Hepatogastroenterology; 2005 Mar 15; 52(61):289-92. PubMed ID: 15783052
    [Abstract] [Full Text] [Related]

  • 24. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z, Shi L, Zhang H, Shao Y, Wang Y, Lin Y, Li X, Bai C.
    Clin Immunol; 2011 Jan 15; 138(1):23-32. PubMed ID: 21041120
    [Abstract] [Full Text] [Related]

  • 25. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z, Tang C, Xu S, Zhang B, Zhang X, Moyana T, Yang J, Xiang J.
    Cell Mol Immunol; 2007 Aug 15; 4(4):277-85. PubMed ID: 17764618
    [Abstract] [Full Text] [Related]

  • 26. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G, Gückel B, Wallwiener D, Moldenhauer G.
    Clin Cancer Res; 1999 Jan 15; 5(1):171-80. PubMed ID: 9918216
    [Abstract] [Full Text] [Related]

  • 27. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.
    Clin Cancer Res; 2007 Mar 15; 13(6):1857-67. PubMed ID: 17363542
    [Abstract] [Full Text] [Related]

  • 28. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis.
    Hiraki A, Ono T, Tanaka M, Kiura K, Ueoka H, Kawai H, Harada M, Nakayama E, Noguchi Y.
    Anticancer Res; 2001 Mar 15; 21(4A):2561-7. PubMed ID: 11724322
    [Abstract] [Full Text] [Related]

  • 29. Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture.
    Foster AE, Forrester K, Gottlieb DJ, Barton GW, Romagnoli JA, Bradstock KF.
    Biotechnol Bioeng; 2004 Jan 20; 85(2):138-46. PubMed ID: 14704996
    [Abstract] [Full Text] [Related]

  • 30. Impact of culture medium on the expansion of T cells for immunotherapy.
    Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K.
    Cytotherapy; 2009 Jan 20; 11(7):936-46. PubMed ID: 19903105
    [Abstract] [Full Text] [Related]

  • 31. Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells.
    Curiel TJ, Krug EC, Purner MB, Poignard P, Berens RL.
    J Immunol; 1993 Aug 15; 151(4):2024-31. PubMed ID: 8102155
    [Abstract] [Full Text] [Related]

  • 32. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
    Gervais A, Bouet-Toussaint F, Toutirais O, De La Pintiere CT, Genetet N, Catros-Quemener V.
    Anticancer Res; 2005 Aug 15; 25(3B):2177-85. PubMed ID: 16158961
    [Abstract] [Full Text] [Related]

  • 33. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
    Tam YK, Martinson JA, Doligosa K, Klingemann HG.
    Cytotherapy; 2003 Aug 15; 5(3):259-72. PubMed ID: 12850795
    [Abstract] [Full Text] [Related]

  • 34. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
    Carlsson B, Sadeghi A, Bengtsson M, Wagenius G, Tötterman TH.
    J Immunother; 2008 Sep 15; 31(7):633-43. PubMed ID: 18600181
    [Abstract] [Full Text] [Related]

  • 35. Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells.
    Mackensen A, Wittnebel S, Veelken H, Noppen C, Spagnoli GC, Lindermann A.
    Eur Cytokine Netw; 1999 Sep 15; 10(3):329-36. PubMed ID: 10477389
    [Abstract] [Full Text] [Related]

  • 36. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W, Fong C.
    Cell Mol Immunol; 2004 Jun 15; 1(3):229-34. PubMed ID: 16219173
    [Abstract] [Full Text] [Related]

  • 37. [Development of specific immunotherapy for cancer].
    Fujimoto S, Araki K, Hamasato S, Maeda N, Noguchi Y.
    Hum Cell; 1992 Sep 15; 5(3):247-55. PubMed ID: 1467324
    [Abstract] [Full Text] [Related]

  • 38. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
    Zappasodi R, Di Nicola M, Carlo-Stella C, Mortarini R, Molla A, Vegetti C, Albani S, Anichini A, Gianni AM.
    Haematologica; 2008 Oct 15; 93(10):1523-34. PubMed ID: 18728033
    [Abstract] [Full Text] [Related]

  • 39. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy.
    Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G, Aarvak T.
    J Immunol Methods; 2010 Apr 15; 355(1-2):52-60. PubMed ID: 20171968
    [Abstract] [Full Text] [Related]

  • 40. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
    Melief CJ, Kast WM.
    Semin Cancer Biol; 1991 Oct 15; 2(5):347-54. PubMed ID: 1773050
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.